My colleagues have asked me to raise the issue of the so-called vaccine inequality again. I am referring to our partners from various public institutions, the Caribbean countries. Countries like Benin, Côte d'Ivoire, Morocco, Serbia, Armenia and others. Many of them say that in certain known economic conditions, first of all, there is no possibility of getting vaccines. Secondly, they recall that a number of countries have been on a vaccine purchasing waiting list. Thirdly, they express considerable surprise that not all vaccines have received international recognition by the World Health Organization or other institutions, though they were recognized in national jurisdictions. I am talking about Russian vaccines, of course — Lidia Mikheeva, Secretary, Civic Chamber of the Russian Federation; Chairperson of the Board, Private Law Research Centre under the President of the Russian Federation named after S.S. Alexeev.
If we are building our own epidemic safety system, which will be less dependent on imports or will not depend on foreign intervention at all, we must understand the cost of this system. For a domestic product that is produced in the amount of, say, 10–20 million doses, it cannot be cheaper than a similar product produced abroad by pharmaceutical tycoons in the amount of 200–300–500 million doses. <...> We want at least a return on investment in the foreseeable future — Konstantin Chernov, Director of Development, Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences.